StockNews.AI
MCRB
StockNews.AI
118 days

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

1. MCRB will hold Q1 2025 financial results call on May 7. 2. Company's SER-155 therapy shows significant efficacy in bloodstream infections. 3. Seres previously launched FDA-approved VOWST therapy sold to Nestlé. 4. MCRB targets treatment for various medically vulnerable patient populations. 5. Webcast replay available for 21 days post-event on company's website.

4m saved
Insight
Article

FAQ

Why Bullish?

The successful development of SER-155 positions MCRB favorably in the market. Previous launches like VOWST already boosted investor confidence and stock value.

How important is it?

The call will detail pivotal financial results and updates, impacting investor perception. SER-155's promising data enhances chance of favorable market outcomes.

Why Long Term?

As SER-155 advances through clinical trials, its approval could lead to substantial market expansion and revenue growth. Historical examples show FDA-approved therapies can yield long-term stock benefits.

Related Companies

NESTLECELGAMGN
April 23, 2025 07:00 ET  | Source: Seres Therapeutics, Inc. CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. About Seres TherapeuticsSeres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com. Investor and Media Contact:  IR@serestherapeutics.com Carlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com

Related News